Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.71 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | IGF1R | P08069 | 3/20 | 0.61 |
| ▸ | MC4R | P32245 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4486265 | 1.00 | KMT2A (0.71) | KMT2AMEN1OPRM1OPRD1GAA | |
| SCHEMBL4474689 | 1.00 | KMT2A (0.71) | KMT2AMEN1OPRM1OPRD1GAA | |
| SCHEMBL4466517 | 1.00 | KMT2A (0.71) | KMT2AMEN1OPRM1OPRD1GAA | |
| SCHEMBL4468315 | 1.00 | KMT2A (0.71) | KMT2AMEN1OPRM1OPRD1GAA | |
| SCHEMBL18704990 | 0.89 | KMT2A (0.73) | KMT2AMEN1OPRM1OPRD1GAA | |
| SCHEMBL2796836 | 0.86 | GAA (0.82) | KMT2AMEN1OPRM1OPRD1GAA | |
| SCHEMBL10746494 | 0.86 | GAA (0.82) | KMT2AMEN1OPRM1OPRD1GAA | |
| SCHEMBL4470929 | 0.86 | IGF1R (0.57) | KMT2AMEN1OPRM1OPRD1GAA | |
| SCHEMBL20965556 | 0.86 | KMT2A (0.69) | KMT2AMEN1OPRM1OPRD1GAA | |
| SCHEMBL24672691 | 0.85 | GAA (0.75) | KMT2AMEN1OPRM1OPRD1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576086-B2 | N1-benzyl-N4-(phenylpropane-2-yl-3-ol)piperazine; triple action on hydroxytryptamine (5-HT), noradrenalin (NA)and dopamine(DA); on brain synapses; cytochrome P-450 monooxygenase enzyme system antagonists; enzyme inhibitors; side effect reduction | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2009-08-18 | — | — | US | claimed |
| US-20050267121-A1 | Aralkyl-alcohol peiperazine derivatives adn their uses as antidepressant | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2005-12-01 | — | — | US | claimed |
| US-7576086-B2 | N1-benzyl-N4-(phenylpropane-2-yl-3-ol)piperazine; triple action on hydroxytryptamine (5-HT), noradrenalin (NA)and dopamine(DA); on brain synapses; cytochrome P-450 monooxygenase enzyme system antagonists; enzyme inhibitors; side effect reduction | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2009-08-18 | — | — | US | disclosed |
| US-20050267121-A1 | Aralkyl-alcohol peiperazine derivatives adn their uses as antidepressant | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267121-A1 | Aralkyl-alcohol peiperazine derivatives adn their uses as antidepressant | AANAT, GAP43, TPH2 | KMT2A 3071/4885MEN1 3476/4885OPRM1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.